{
    "relation": [
        [
            "",
            "Raltegravir 800 mg q.d.",
            "Raltegravir 400 mg b.i.d."
        ],
        [
            "Description",
            "Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA\u2122 for 96 weeks",
            "Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA\u2122 for 96 weeks"
        ]
    ],
    "pageTitle": "A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00745823?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990900.28/warc/CC-MAIN-20150728002310-00068-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 854012536,
    "recordOffset": 853996597,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Comparator: Raltegravir 400 mg b.i.d. Drug: Experimental: Raltegravir 800 mg q.d. Drug: TRUVADA\u2122 Interventions: HIV Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: March 6, 2012 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Raltegravir 800 mg q.d. \u00a0 \u00a0 Raltegravir 400 mg b.i.d. \u00a0 STARTED \u00a0 \u00a0 386 \u00a0 \u00a0 389 \u00a0 TREATED Week 0 - 96 \u00a0 \u00a0 382 \u00a0 \u00a0 388 \u00a0 COMPLETED \u00a0 \u00a0 1 \u00a0 \u00a0 3 \u00a0 NOT COMPLETED \u00a0 \u00a0 385 \u00a0 \u00a0 386 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 20 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}